Methotrexate is under clinical development by Aldeyra Therapeutics and currently in Phase II for Retinitis Pigmentosa (Retinitis). According to GlobalData, Phase II drugs for Retinitis Pigmentosa (Retinitis) have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Methotrexate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Methotrexate overview
Methotrexate is under development for the treatment of proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma and retinal detachment. The drug candidate is administered through intravitreal route. It acts by targeting dihydrofolate reductase.
Aldeyra Therapeutics overview
Aldeyra Therapeutics, is a biotechnology company. It offers treatment of immune-mediated diseases. The company offers product pipeline includes Reproxalap, an aldehyde trap for the treatment of allergic conjunctivitis and dry eye disease; ADX-2191 to treat proliferative vitreoretinopathy and intraocular lymphoma; and ADX-103/10X for the treatment of retinal disease. Aldeyra Therapeutics utilizes reactive aldehyde species (RASP), dihydrofolate reductase (DHFR) and chaperome (CHP) inhibition for advancing its pipeline products. The company’s drug candidates offer treatment for inflammation and genetic diseases caused by inborn errors of aldehyde metabolism. Aldeyra Therapeutics is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Methotrexate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
